US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TuHURA Biosciences, Inc.

1.81

-0.1400-7.18%

Post-market: 1.80-0.0100-0.55%19:55 EDT

Volume:591.85K

Turnover:1.09M

Market Cap:109.90M

PE:-2.73

High:1.99

Open:1.99

Low:1.80

Close:1.95

52wk High:4.44

52wk Low:0.4100

Shares:60.72M

Float Shares:54.29M

Volume Ratio:0.69

T/O Rate:1.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6627

EPS(LYR):-1.2136

ROE:-418.06%

ROA:-60.16%

PB:6.66

PE(LYR):-1.49

Loading ...

Overview Company News Filings

These 16 stocks are a short seller's dream - likely losers no matter what the market does

TuHURA Biosciences Inc expected to post a loss of 13 cents a share - Earnings Preview

These 16 stocks are a short seller's dream - likely losers no matter what the market does

TuHURA Biosciences names Craig Tendler to CMO-like role while he remains on board

Press Release: Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy

TuHURA Biosciences Regains Nasdaq Minimum Bid Price Compliance

Tuhura Biosciences Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS

TuHURA Biosciences CEO James Bianco to Present at Citizens Life Science Conference

Tuhura Biosciences Files IND for TBS-2025 in Blood Cancer Treatment

Tuhura Biosciences Inc - Plans Phase 2 Study for Mutnpm1 R/R Aml in Q2 2026, Preliminary Stage 1 Results in Q3 2026

THOMSON REUTERS

Tuhura Files Investigational New Drug Application for Tbs-2025 in the Treatment of Blood-Related Cancers

THOMSON REUTERS

TuHURA Biosciences to Present at Oppenheimer Healthcare Life Sciences Conference

TuHURA Biosciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

FDA Grants Orphan Drug Designation to TuHURA Biosciences' IFx-2.0 for Cutaneous Melanoma

Tuhura Biosciences Received FDA Orphan Drug Designation for Ifx-2.0 for the Treatment of Stage Iib to Stage Iv Cutaneous Melanoma

THOMSON REUTERS

Nasdaq Warns Tuhura Biosciences Over Minimum Bid Price Compliance

Tuhura Biosciences Unveils Cancer Immunotherapy Advances Targeting Resistance with Three Novel Technologies

TuHURA Biosciences Price Target Cut to $10.00/Share From $12.00 by HC Wainwright & Co.

TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/HURA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":1.81,"timestamp":1774641600000,"preClose":1.95,"halted":0,"volume":591846,"hourTrading":{"tag":"盘后","latestPrice":1.8,"preClose":1.81,"latestTime":"19:55 EDT","volume":15589,"amount":28166.7458,"timestamp":1774655734408,"change":-0.01,"changeRate":-0.005525,"amplitude":0.022099},"delay":0,"changeRate":-0.07179487179487175,"floatShares":54286373,"shares":60720508,"eps":-0.662671,"marketStatus":"Market Closed","change":-0.14,"latestTime":"03-27 16:00:00 EDT","open":1.99,"high":1.99,"low":1.8,"amount":1088869.689033,"amplitude":0.097436,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.662671,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.95,"preHourTrading":{"tag":"盘前","latestPrice":1.98,"preClose":1.95,"latestTime":"09:29 EDT","volume":1565,"amount":3085.927722,"timestamp":1774618199999,"change":0.03,"changeRate":0.015385,"amplitude":0.035897},"postHourTrading":{"tag":"盘后","latestPrice":1.8,"preClose":1.81,"latestTime":"19:55 EDT","volume":15589,"amount":28166.7458,"timestamp":1774655734408,"change":-0.01,"changeRate":-0.005525,"amplitude":0.022099},"volumeRatio":0.688331},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":54286373,"roa":"-60.16%","roe":"-418.06%","lyrEps":-1.213628,"volumeRatio":0.688331,"shares":60720508,"dividePrice":0,"high":1.99,"amplitude":0.097436,"preClose":1.95,"low":1.8,"week52Low":0.41,"pbRate":"6.66","week52High":4.44,"institutionHeld":0,"latestPrice":1.81,"eps":-0.662671,"divideRate":0,"volume":591846,"delay":0,"ttmEps":-0.662671,"open":1.99,"prevYearClose":0.7567,"prevWeekClose":1.94,"prevMonthClose":1.67,"prevQuarterClose":0.7567,"fiveDayClose":1.94,"twentyDayClose":1.67,"sixtyDayClose":0.7586},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"HURA","fiscalQuarterEnding":"2025/09","expectedEps":-0.15,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-14","symbol":"HURA","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-05-15","symbol":"HURA","fiscalQuarterEnding":"2025/03","expectedEps":-0.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-03-31","symbol":"HURA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"HURA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-1.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1755316800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2026-03-27","current":-2.73137,"percent":0.758523,"low":-15.284879,"twenty":-8.259713,"median":-4.911411,"eighty":-3.465457,"high":-0.912265,"avg":-5.750471,"sd":2.972315,"marketCap":118404990},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-06","current":-5.370723,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"marketCap":126236344},{"date":"2025-06-13","current":-4.86896,"twenty":-10.273819,"median":-7.961523,"eighty":-5.965405,"marketCap":114442640},{"date":"2025-06-20","current":-5.01763,"twenty":-10.268299,"median":-7.907165,"eighty":-5.77585,"marketCap":117937071},{"date":"2025-06-27","current":-4.255694,"twenty":-10.254133,"median":-7.8568,"eighty":-5.590128,"marketCap":100028109},{"date":"2025-07-03","current":-4.911411,"twenty":-10.238281,"median":-7.856432,"eighty":-5.456208,"marketCap":115440443},{"date":"2025-07-11","current":-4.990628,"twenty":-10.201312,"median":-7.766145,"eighty":-5.256797,"marketCap":117302386},{"date":"2025-07-18","current":-5.010432,"twenty":-10.182292,"median":-7.688203,"eighty":-5.039996,"marketCap":117767871},{"date":"2025-07-25","current":-5.624358,"twenty":-10.127376,"median":-7.668851,"eighty":-5.052895,"marketCap":132197927},{"date":"2025-08-01","current":-4.911411,"twenty":-10.049579,"median":-7.615053,"eighty":-5.052895,"marketCap":115440443},{"date":"2025-08-08","current":-4.812391,"twenty":-9.994663,"median":-7.555364,"eighty":-5.037142,"marketCap":113113015},{"date":"2025-08-15","current":-4.975285,"twenty":-9.907714,"median":-7.528032,"eighty":-5.017728,"marketCap":138129515},{"date":"2025-08-22","current":-5.245681,"twenty":-9.861951,"median":-7.477167,"eighty":-5.037142,"marketCap":145636554},{"date":"2025-08-29","current":-5.065417,"twenty":-9.847676,"median":-7.326779,"eighty":-5.052895,"marketCap":140631862},{"date":"2025-09-05","current":-4.560678,"twenty":-9.79276,"median":-7.254296,"eighty":-5.013311,"marketCap":126618722},{"date":"2025-09-12","current":-4.668836,"twenty":-9.696332,"median":-7.110931,"eighty":-4.956091,"marketCap":129621538},{"date":"2025-09-19","current":-4.65081,"twenty":-9.618099,"median":-7.053585,"eighty":-4.911411,"marketCap":129121069},{"date":"2025-09-26","current":-4.416467,"twenty":-9.555338,"median":-6.959639,"eighty":-4.875184,"marketCap":122614968},{"date":"2025-10-03","current":-4.704889,"twenty":-9.532456,"median":-6.792598,"eighty":-4.824615,"marketCap":130622476},{"date":"2025-10-10","current":-4.65081,"twenty":-9.500422,"median":-6.659051,"eighty":-4.759515,"marketCap":129121069},{"date":"2025-10-17","current":-4.326335,"twenty":-9.445506,"median":-6.451252,"eighty":-4.704889,"marketCap":120112622},{"date":"2025-10-24","current":-4.019886,"twenty":-9.386014,"median":-6.151486,"eighty":-4.692197,"marketCap":111604644},{"date":"2025-10-31","current":-4.470546,"twenty":-9.301564,"median":-5.965405,"eighty":-4.668836,"marketCap":124116376},{"date":"2025-11-07","current":-4.416467,"twenty":-9.208999,"median":-5.850391,"eighty":-4.621968,"marketCap":122614968},{"date":"2025-11-14","current":-3.677385,"twenty":-9.18008,"median":-5.798151,"eighty":-4.596731,"marketCap":102095729},{"date":"2025-11-21","current":-2.774116,"twenty":-9.039762,"median":-5.662432,"eighty":-4.565822,"marketCap":81244064},{"date":"2025-11-28","current":-3.500461,"twenty":-8.84257,"median":-5.63426,"eighty":-4.556086,"marketCap":102516170},{"date":"2025-12-05","current":-3.465457,"twenty":-8.730961,"median":-5.593729,"eighty":-4.544729,"marketCap":101491008},{"date":"2025-12-12","current":-1.811489,"twenty":-8.705462,"median":-5.561421,"eighty":-4.506599,"marketCap":53052117},{"date":"2025-12-19","current":-1.552105,"twenty":-8.587093,"median":-5.505534,"eighty":-4.470546,"marketCap":45455669},{"date":"2025-12-26","current":-1.707387,"twenty":-8.521606,"median":-5.445058,"eighty":-4.45252,"marketCap":50003338},{"date":"2026-01-02","current":-1.568888,"twenty":-8.50549,"median":-5.407919,"eighty":-4.416467,"marketCap":45947208},{"date":"2026-01-09","current":-1.564327,"twenty":-8.469228,"median":-5.371294,"eighty":-4.409256,"marketCap":45813623},{"date":"2026-01-16","current":-1.57656,"twenty":-8.46117,"median":-5.317787,"eighty":-4.331172,"marketCap":46171874},{"date":"2026-01-23","current":-1.408413,"twenty":-8.46117,"median":-5.267885,"eighty":-4.319125,"marketCap":41247441},{"date":"2026-01-30","current":-1.163138,"twenty":-8.430269,"median":-5.249422,"eighty":-4.265631,"marketCap":34064204},{"date":"2026-02-06","current":-0.912265,"twenty":-8.395844,"median":-5.227655,"eighty":-4.145319,"marketCap":26717023},{"date":"2026-02-13","current":-2.881928,"twenty":-8.370916,"median":-5.188669,"eighty":-4.09774,"marketCap":84401506},{"date":"2026-02-20","current":-2.301396,"twenty":-8.352484,"median":-5.119354,"eighty":-3.87886,"marketCap":67399763},{"date":"2026-02-27","current":-3.358794,"twenty":-8.340447,"median":-5.054798,"eighty":-3.490101,"marketCap":98367222},{"date":"2026-03-06","current":-3.234394,"twenty":-8.312748,"median":-5.017712,"eighty":-3.42514,"marketCap":94723992},{"date":"2026-03-13","current":-4.063726,"twenty":-8.270771,"median":-4.990628,"eighty":-3.42514,"marketCap":119012195},{"date":"2026-03-20","current":-3.71126,"twenty":-8.265757,"median":-4.95929,"eighty":-3.463659,"marketCap":108689709},{"date":"2026-03-27","current":-4.042992,"twenty":-8.259713,"median":-4.911411,"eighty":-3.465457,"marketCap":118404990}],"updateTime":1774756784247},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623387604","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623387604?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:04","pubTimestamp":1774717440,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4023","GETY","BYND","BK4139","CD","FLYX","NNE","BK4008","NFE","EVCM","ATLN","BK4606","BK4161","BK4604","PDYN","RXT","BK4603","NNEX","LCID","HURA","SLS","CRDF","BK4548","BK4116","BK4608","BK4138","BK4082","SERV","BK4144","BK4212","CV","BK4182"],"gpt_icon":0},{"id":"2622805616","title":"TuHURA Biosciences Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622805616","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622805616?lang=en_us&edition=fundamental","pubTime":"2026-03-28 05:35","pubTimestamp":1774647306,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc  expected to post a loss of13cents a share - Earnings Preview TuHURA Biosciences Inc HURA.OQ HURA.O is expected to  report resultson March 31 (estimated) for the period ending D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F253:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2622826019","title":"These 16 stocks are a short seller's dream - likely losers no matter what the market does","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826019?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:05","pubTimestamp":1774613100,"startTime":"0","endTime":"0","summary":"Borrowing costs eat into trading profits. These stocks are less expensive to short.Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column.Short sellers have good odds of turning a profit with these equities - even if the Iran conflict is soon resolved, oil prices decline, U.S. interest rates are cut, or any other events that are likely to make the market soar transpire.The 16 stocks listed below earned their spot because their shares are expensive to borrow in the share-lending market. That means relatively few short sellers are willing to consider them, which in turn means that they most likely are trading for more than they would otherwise. And that means their stock price is more likely to decline.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","HURA","BK4608","FLYX","BK4144","BK4182","BK4548","SLS","BK4604","BK4212","BK4139","CRDF","GETY","BK4161","CV","NNEX","BK4138","BK4082","ATLN","BK4008","NNE","BK4606","BK4603","SERV","RXT","BK4116","CD","EVCM","PDYN","BK4077","NFE","LCID","BYND"],"gpt_icon":0},{"id":"2621708657","title":"TuHURA Biosciences names Craig Tendler to CMO-like role while he remains on board","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708657","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708657?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:46","pubTimestamp":1774266380,"startTime":"0","endTime":"0","summary":"TuHURA said Craig Tendler will provide strategic and operational services consistent with those of a chief medical officer while continuing as a board member.He will oversee clinical development strategy and operations for the pipeline, including the VISTA-inhibiting antibody TBS-2025.Tendler previously served as Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs at Johnson & Johnson Innovative Medicine Research & Development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9jMBr7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNV92.GBP","IE0034235303.USD","BK4588","LU0345770993.USD","LU0889566641.SGD","SG9999002224.SGD","LU1267930813.SGD","LU0289739699.SGD","IE00BFXG1179.USD","LU2347655156.SGD","HURA","LU1023059063.AUD","IE0009355771.USD","IE00B19Z3B42.SGD","LU1074936037.SGD","LU1066051225.USD","IE00BGHQF631.EUR","LU0203347892.USD","LU1732799900.SGD","BK4139","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU0985320562.USD","LU1221951129.SGD","LU0114720955.EUR","LU0432979614.USD","LU1244550577.SGD","JNJ","LU1496350502.SGD","LU0795875169.SGD","SG9999002232.USD","BK4504","LU1066051498.USD","LU2505996509.AUD","LU0683600562.USD","LU1066051811.HKD","IE00BLSP4239.USD","LU2430703095.HKD","IE00BBT3K403.USD","LU0640476718.USD","BK4581","LU0795875086.SGD","IE00BLSP4452.SGD","BK4532","IE00BDGV0183.EUR","LU0098860793.USD","LU0689626769.HKD","LU1280957306.USD","IE00BJT1NW94.SGD","LU2129689431.USD"],"gpt_icon":0},{"id":"2621641708","title":"Press Release: Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2621641708","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621641708?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:45","pubTimestamp":1774266300,"startTime":"0","endTime":"0","summary":"Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology. Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales. Dr. Tendler, a distinguished thirty-year industry veteran, will provide strategic and operational services consistent with those of a CMO while continuing his role as a member on the TuHURA Board of Directors. Dr. Tendler is a seasoned professional, previously serving as the Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs of Johnson & Johnson Innovative Medicine Research","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JNJ","LU2089984988.USD","LU1929549753.HKD","IE00B4R5TH58.HKD","LU1280957306.USD","LU1244550494.USD","IE00B19Z3B42.SGD","BK4568","BK4504","LU1059921491.USD","LU0124676726.USD","LU0203347892.USD","LU0640476718.USD","LU0889566641.SGD","LU0466842654.USD","IE00BDGV0183.EUR","LU1032466523.USD","LU1221951129.SGD","LU0058720904.USD","LU2592432038.USD","LU1261432733.SGD","BK4007","LU1066051498.USD","SG9999001440.SGD","R","LU0203345920.USD","IE00BJJMRZ35.SGD","LU1196500208.SGD","LU1221951046.USD","LU1162221912.USD","LU2129689605.HKD","IE0001KFT4U8.USD","LU1894683264.USD","IE00BJT1NW94.SGD","LU2129689514.USD","LU2129689431.USD","IE00B1BXHZ80.USD","HURA","LU0792757196.USD","LU2468319806.SGD","LU1496350502.SGD","LU0098860793.USD","LU1032955483.USD","LU1585245621.USD","LU1066053197.SGD","LU1894683348.USD","LU0985320562.USD","IE0034235303.USD","LU2602419157.SGD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2617631086","title":"Tuhura Biosciences Publishes Corporate Presentation on Overcoming Resistance to Cancer Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2617631086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617631086?lang=en_us&edition=fundamental","pubTime":"2026-03-07 00:47","pubTimestamp":1772815649,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL8P6FLt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2614285398","title":"TuHURA Biosciences Regains Nasdaq Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2614285398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614285398?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:30","pubTimestamp":1772195425,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc. said it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement under Listing Rule 5550 after its shares closed at or above $1.00 for 11 consecutive business days, and Nasdaq has closed the matter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL8gQ5L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2614853663","title":"Tuhura Biosciences Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2614853663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614853663?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:30","pubTimestamp":1772195400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nTUA19B3GC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2614072614","title":"TuHURA Biosciences CEO James Bianco to Present at Citizens Life Science Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614072614","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614072614?lang=en_us&edition=fundamental","pubTime":"2026-02-25 06:20","pubTimestamp":1771971618,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences CEO James Bianco to Present at Citizens Life Science Conference               TuHURA Biosciences Inc. said its CEO, Dr. James Bianco, will present at the Citizens Life Science Confe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL7gl4T0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2612752454","title":"Tuhura Biosciences Files IND for TBS-2025 in Blood Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2612752454","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612752454?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:45","pubTimestamp":1771332332,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Files IND for TBS-2025 in Blood Cancer Treatment               TuHURA Biosciences Inc. has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL34f3K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2612764454","title":"Tuhura Biosciences Inc - Plans Phase 2 Study for Mutnpm1 R/R Aml in Q2 2026, Preliminary Stage 1 Results in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612764454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612764454?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:45","pubTimestamp":1771332300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA1DQTZ1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2612454767","title":"Tuhura Files Investigational New Drug Application for Tbs-2025 in the Treatment of Blood-Related Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2612454767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612454767?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:45","pubTimestamp":1771332300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA1DQTZ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2610926617","title":"TuHURA Biosciences to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2610926617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610926617?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:45","pubTimestamp":1770900313,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on February 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL8tHtJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2608879241","title":"TuHURA Biosciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879241?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:11","pubTimestamp":1770124260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2026 08:11 ET (13:11 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2608691418","title":"FDA Grants Orphan Drug Designation to TuHURA Biosciences' IFx-2.0 for Cutaneous Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2608691418","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608691418?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:45","pubTimestamp":1770036322,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences, Inc. announced that the U.S. Food and Drug Administration  Office of Orphan Products Development has granted Orphan Drug Designation to its candidate IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma. This designation provides TuHURA with benefits including seven years of market exclusivity, increased FDA engagement and assistance, tax credits for certain research, research grants, and a waiver of the New Drug Application user fee. No other beneficiary organizations were mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on February 02, 2026, and is solely responsible for the informatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL3l1ggn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"gpt_icon":0},{"id":"2608869924","title":"Tuhura Biosciences Received FDA Orphan Drug Designation for Ifx-2.0 for the Treatment of Stage Iib to Stage Iv Cutaneous Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2608869924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608869924?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:45","pubTimestamp":1770036300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1XY2QY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2607386021","title":"Nasdaq Warns Tuhura Biosciences Over Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2607386021","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607386021?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:01","pubTimestamp":1769806881,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc. has received a notice from Nasdaq indicating that its common stock has traded below the $1.00 minimum bid price requirement for 35 consecutive business days, putting the company out of compliance with Nasdaq Listing Rule 5550. The company has been granted a 180-day grace period, until July 28, 2026, to regain compliance. If it does not meet the requirement within this period, Tuhura may be eligible for a second 180-day extension, provided it meets other initial listing standards and notifies Nasdaq of its intention to address the deficiency, potentially including a reverse stock split. Failure to regain compliance could result in delisting from the Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDLcg1Ck6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2603628365","title":"Tuhura Biosciences Unveils Cancer Immunotherapy Advances Targeting Resistance with Three Novel Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2603628365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603628365?lang=en_us&edition=fundamental","pubTime":"2026-01-15 07:19","pubTimestamp":1768432740,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences Inc. has released a corporate presentation outlining its progress in developing immuno-oncology therapeutics aimed at overcoming resistance to cancer immunotherapies. The company’s lead asset, IFx-2.0, is currently in a Phase 3 front-line study for Merkel Cell Cancer, with top-line data expected in the first half of 2027. This trial is being conducted under a Special Protocol Assessment  agreement with the U.S. Food and Drug Administration. Preliminary data from a Phase 1/2 study of IFx-2.0 will be presented at ASCO 2026. Tuhura’s pipeline includes a second asset, TBS-2025, targeting VISTA in NPM1-mutated acute myeloid leukemia , which will enter Phase 2 trials in early 2026, with data anticipated later that year. A third program involving bi-specific antibody-drug conjugates  is expected to reach in vivo proof-of-concept in 2026, opening potential partnering opportunities. The company reports a cash position that supports advancement through multiple key milestones.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL758LqY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2602378399","title":"TuHURA Biosciences Price Target Cut to $10.00/Share From $12.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2602378399","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602378399?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:56","pubTimestamp":1767959760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 06:56 ET (11:56 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"gpt_icon":0},{"id":"2602327025","title":"TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2602327025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602327025?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:16","pubTimestamp":1767957361,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns lowered the firm’s price target on TuHURA Biosciences (HURA) to $10 from $12 and keeps a Buy rating on the sha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-10-from-12-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-10-from-12-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HURA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}]}}